RecruitingNCT06782789
An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
96 participants
Start Date
Mar 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The study is pilot, observational, retrospective, Italian multicenter study.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Histologically confirmed diagnosis of R/R DLBCL.
- Patientswho received at least one dose of tafasitamab in association with lenalidomide under the NPP (D.M. 7 Sep 2017), between April 2022 and December 2022.
- Age ≥ 18 years at enrollment.
- Signature of written informed consent (if applicable).
Exclusion Criteria1
- \) R/R DLBCL patients who received tafasitamab in association with lenalidomide in a clinical trial context.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06782789
Related Trials
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT0513102262 locations
Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients
NCT074731671 location
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
NCT0718855839 locations
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
NCT073978321 location
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
NCT060430111 location